Roivant Sciences Ltd. officer and director Mayukh Sukhatme filed a Form 144 notice of proposed sale on November 10, 2026, covering 173,725 shares of common stock to be sold on NASDAQ.

Key Highlights

  • Proposed sale: Mayukh Sukhatme intends to sell 173,725 shares of Roivant Sciences common stock with an aggregate market value of $7,122,725.00.
  • Source of shares: The securities were acquired on November 10, 2026, through Performance Stock Units granted by the issuer, with payment described as "Services Rendered."
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker for the proposed sale.
  • Shares outstanding: According to the filing, 724,561,460 shares of common stock were outstanding at the time of notice.
  • Prior sales in past 3 months: Sukhatme sold a combined 1,000,000 shares in six transactions between August 14 and August 21, 2026, generating gross proceeds totaling approximately $36,519,316.93.
  • Approximate sale date: The proposed sale is expected to occur on November 10, 2026, on NASDAQ.

Sukhatme Form 144 Details: Performance Stock Units and Prior Sales History

According to the filing, Mayukh Sukhatme, identified as both an officer and director of Roivant Sciences Ltd. (NASDAQ:ROIV), submitted a Form 144 notice dated November 10, 2026. The notice covers a proposed sale of 173,725 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The aggregate market value of the proposed sale is listed as $7,122,725.00.

The filing states the shares were acquired on November 10, 2026, via a Performance Stock Unit transaction from the issuer, with the nature of payment described as "Services Rendered." The issuer's address is listed as 7th Floor, 50 Broadway, London, United Kingdom, SW1H 0DB, and the SEC file number is 001-40782.

The filing also discloses six sales of Roivant common stock by Sukhatme during the three months preceding the notice. Those sales took place between August 14, 2026, and August 21, 2026, covering a total of 1,000,000 shares. Individual transactions ranged from 17,519 shares on August 20, 2026, with gross proceeds of $653,407.89, to 284,707 shares on August 17, 2026, with gross proceeds of $10,320,571.81. The combined gross proceeds from all six prior transactions, as listed in the filing, total approximately $36,519,316.93.

What Was Disclosed

Mayukh Sukhatme, an officer and director of Roivant Sciences Ltd., filed a Form 144 notice proposing the sale of 173,725 common shares acquired through Performance Stock Units, with an aggregate market value of $7,122,725.00, on NASDAQ on November 10, 2026.